This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

About the NKI

The Netherlands Cancer Institute was established on October 10, 1913. The founders, Rotgans, professor of Surgery, De Bussy, publisher, and De Vries, professor of Pathology, wanted to create a cancer institute 'where patients suffering from malignant growths could be treated adequately and where cancer and related diseases could be studied'. They bought a house on one of the canals in Amsterdam and named it the 'Antoni van Leeuwenhoek Huis', after the famous Dutch microscopist. The clinic had room for 17 patients, while the laboratory could accommodate 8 to 10 scientists.

Nowadays, The Netherlands Cancer Institute accommodates approximately 650 scientists and scientific support personnel. The Antoni van Leeuwenhoek Hospital has 185 medical specialists, 180 beds, an out-patients clinic with around 106,000 visits, 12 operating theaters and 11 irradiotion units for radiotherapy. It is the only dedicated cancer center in The Netherlands and maintains an important role as a national and international center of scientific and clinical expertise, development and training.

News

  • 04Feb 2020

    Impact NKI research highlighted by ASCO

    Research led by Lisette Rozeman was selected by the American Society of Clinical Oncology for inclusion in the Clinical Cancer Advances 2020, which highlights the most impactful research advances of the past year.

    Read More
  • 31Jan 2020

    High-dose chemotherapy in high-risk breast cancer shows improved survival in 20-year follow-up

    A follow-up study after 20 years shows that the survival rate for women with breast cancer and ten or more affected lymph nodes in the armpit is 15% higher after high-dose chemotherapy than after the conventional dose. Moreover, the patients did not show an increase in secondary cancers or serious cardiovascular diseases. The follow-up study, coordinated by Tessa Steenbruggen (Netherlands Cancer Institute) and Lars Steggink (UMCG), was published in JAMA Oncology at January 30.

    Read More
  • 27Jan 2020

    Thesis defense Ellen Derissen - do medicines make it into cells?

    PhD student Ellen Derissen investigated to what extend those medicines manage to get into the patients' cells and be activated once arrived. Only then they can kill cancer cells.

    Read More
  • 20Jan 2020

    Thesis defense Merel van Nuland - Towards patient-tailored dosing of anti-cancer drugs

    On 22 January, pharmacologist Merel van Nuland will defend her thesis on the clinical pharmacology of anti-cancer drugs. Merel did her PhD research at the NKI and will defend her thesis at Utrecht University. Lots of success!

    Read More

Board of Directors

Overview boards and commissions

Restaurant.jpg

Internal procedures

The NKI has adopted several regulations and procedures which help us organize our research along national and international standards. The most important regulations and procedures can be found here.

Read more

Seminar.jpg

Technology Transfer Office

The NKI has a mission to beat cancer and performs world-beating research to increase our understanding of this disease. The knowledge that is gained in this way sometimes opens avenues for development of e.g. novel treatments or new diagnostic tests. To achieve its mission, NKI actively collaborates with private companies that have the knowledge and the means to develop products based on research results obtained at our institution.

Go to the site of the Technology Transfer Office

Scientific Annual Reports (SAR)

Brochures

Occupation

Total783
Group Leaders51
Postdocs191
PhD Students187
Technicians208
Other146

Facts

  • Silhoutten

    44

    Nationalities

  • Silhoutten

    542

    Publications

  • Horloge

    783

    Employees

  • Silhoutten

    91M

    Project
    Grants

  • Bed

    51

    Research
    Groups

Key Figures Research

Publications in 2016 805
Total impact of publications in 2014 3935
Avarage impact of publications 2014 6.8

Key Figures Research

Number of divisions 15
Number of Reseach groups 51
Share this page